Profile picture

Doctor Thomas Mondritzki

Bayer AG, Wuppertal (Germany)
Membership: HFA Member
Follow
Logo ESC

Contributor content

Real-world evidence for patient phenotypes in heart failure with preserved ejection fraction
Presentation
Real-world evidence for patient phenotypes in heart failure with preserved ejection fraction
Read more
Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
Presentation
Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
Read more
Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?
Presentation
Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?
Read more

ESC 365 is supported by

novartis Explore sponsored resources